Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice.

Publisher: SAGE Publications Country of Publication: England NLM ID: 9204265 Publication Model: Print Cited Medium: Print ISSN: 0961-2033 (Print) Linking ISSN: 09612033 NLM ISO Abbreviation: Lupus Subsets: MEDLINE

Publication: London : SAGE Publications
Original Publication: Houndmills, Basingstoke, Hampshire, UK : Scientific & Medical Division, Macmillan Press Ltd., c1991-

Adjuvants, Immunologic/*pharmacology ; Lupus Nephritis/*physiopathology ; Oligodeoxyribonucleotides/*pharmacology; Animals ; Antibodies, Antinuclear/blood ; Blood Urea Nitrogen ; Complement C3/analysis ; CpG Islands ; Creatinine/blood ; Cytokines/blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Immunoglobulin G/analysis ; Immunohistochemistry ; Interleukin-6/biosynthesis ; Kidney/pathology ; Kidney Glomerulus/immunology ; Lupus Nephritis/immunology ; Lupus Nephritis/pathology ; Lupus Nephritis/urine ; Mice ; Mice, Inbred NZB ; Mice, Inbred Strains ; Oligodeoxyribonucleotides/chemical synthesis ; Proteinuria ; Spleen/immunology

The effect of synthetic CpG-oligodeoxynucleotides (CpG-ODN) on the development of lupus nephritis during preactive phase (within seven months of age) in autoimmune lupus NZB x NZWF1 (B/WF1) mice was examined. Treatment of CpG-ODN was started at the age of 2.75 months and continued until 6.25 months. Overt disease began at the age of six months and progressed linearly at the age of 6.75 months in CpG-ODN-treated, but not control ODN-treated (control) groups. Also compared to control group, CpG-ODN-treated mice exhibited a severe glomerulonephritis (GN), with prominent deposits of IgG2a and C3, which paralleled increased titre of IgG2a type anti-nuclear antibody in the blood. Among several cytokines (interleukin, IL-6, IL-4, IL-1alpha, IL-10, interferon-gamma and tumor necrosis factor-alpha) in blood, IL-6 production paralleled the development of lupus nephritis. The present study suggests that CpG-ODN may enhance IL-6 production. The role of IL-6 in the development of GN will be discussed.

0 (Adjuvants, Immunologic)
0 (Antibodies, Antinuclear)
0 (CPG-oligonucleotide)
0 (Complement C3)
0 (Cytokines)
0 (Immunoglobulin G)
0 (Interleukin-6)
0 (Oligodeoxyribonucleotides)
AYI8EX34EU (Creatinine)

Date Created: 20031212 Date Completed: 20040722 Latest Revision: 20170214

20240104

10.1191/0961203303lu483oa

14667100